Top

Published in:

01-10-2015 | Original Article

Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma

Authors: Yuko Nakamura, Tomoki Kimura, Toru Higaki, Yukiko Honda, Daisuke Komoto, Takuji Yamagami, Makoto Iida, Yasushi Nagata, Yohji Honda, Hiroshi Aikata, Kazuaki Chayama, Kazuo Awai

Published in: Japanese Journal of Radiology | Issue 10/2015

Abstract

Purpose

To investigate the utility of gadoxetate disodium-enhanced hepatic MRI (EOB-MRI) for stereotactic body radiotherapy (SBRT) to treat hepatocellular carcinoma (HCC).

Materials and methods

We divided 30 HCC patients who underwent SBRT into group A (no change in their Child-Pugh score 6 months post-SBRT) and group B (increased score 6 months post-SBRT). EOB-MRI was performed before and 6 months after SBRT. We calculated the liver-spleen contrast (LSC) ratio for each radiation dose area on hepatobiliary phase scans (LSC_before using images obtained before SBRT and LSC_after using images acquired after SBRT) and the weighted LSC (W-LSC) as: [(mean LSC_before (0–30 Gy) × liver volume (0–30 Gy) + mean LSC_before (30 Gy-) × liver volume (30 Gy-))/total liver volume]. Then we compared the W-LSC, percentage of the liver volume exposed to >20 Gy (V20), and mean liver dose in the two groups.

Results

The LSC_after at 48, 40, and 30 Gy to the liver was statistically lower than the unirradiated area of the liver (p < 0.01). Univariate analysis showed that only W-LSC was significantly associated with group B (p = 0.02).

Conclusion

W-LSC was a useful parameter for predicting changes in hepatic function after SBRT.

Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2010;28(25):3994–4005.PubMedCentralCrossRefPubMed

Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52(Suppl 3):1–8.

Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40:1043–59.CrossRef

Takeda A, Takahashi M, Kunieda E, Takeda T, Sanuki N, Koike Y, et al. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol Res. 2008;38(1):60–9.CrossRefPubMed

Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(2):372–9.CrossRefPubMed

Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100.PubMedCentralCrossRefPubMed

Takeda A, Oku Y, Sanuki N, Kunieda E, Koike N, Aoki Y, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol. 2012;104(3):374–8.CrossRefPubMed

Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol. 2001;11(3):240–6.CrossRefPubMed

Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65(2):426–34.CrossRefPubMed

10.

Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230(1):266–75.CrossRefPubMed

11.

Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45(3):133–41.CrossRefPubMed

12.

Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256(3):806–16.CrossRefPubMed

13.

Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology. 2005;237(1):89–98.CrossRefPubMed

14.

Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30(5):1042–6.CrossRefPubMed

15.

Morita K, Namimoto T, Awai K, Komi M, Hashida M, Tsuji T, et al. Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: comparison with gadopentetate dimeglumine. Magn Reson Med. 2011;66(1):213–8.CrossRefPubMed

16.

Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18(8):712–21.CrossRefPubMed

17.

Shinagawa Y, Sakamoto K, Fujimitsu R, Shimakura M, Kora S, Takano K, et al. Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation. Am J Roentgenol. 2012;199(5):1010–7.CrossRef

18.

Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys. 2014;88(2):306–11.CrossRefPubMed

19.

Kimura T, Takahashi S, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y, et al. Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: how should we evaluate treatment effects? Hepatol Res. 2013;43(7):717–27.CrossRefPubMed

20.

Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. Am J Roentgenol. 2013;201(6):W812–20.CrossRef

21.

22.

Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010;83(996):1063–71.PubMedCentralCrossRefPubMed

23.

Okamoto D, Nishie A, Asayama Y, Tajima T, Ishigami K, Kakihara D, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation. Magn Reson Imaging. 2014;32(6):660–4.CrossRefPubMed

24.

Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol. 2009;192(6):1675–81.CrossRef

25.

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.PubMedCentralCrossRefPubMed

26.

Matsumata T, Kanematsu T, Yoshida Y, Furuta T, Yanaga K, Sugimachi K. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg. 1987;11(5):678–81.CrossRefPubMed

27.

Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84(9):1255–9.CrossRefPubMed

Title: Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma
Authors: Yuko Nakamura
Tomoki Kimura
Toru Higaki
Yukiko Honda
Daisuke Komoto
Takuji Yamagami
Makoto Iida
Yasushi Nagata
Yohji Honda
Hiroshi Aikata
Kazuaki Chayama
Kazuo Awai
Publication date: 01-10-2015
Publisher: Springer Japan
Published in: Japanese Journal of Radiology / Issue 10/2015
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-015-0465-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2015

Getting published in Radiology: A Deputy Editor’s perspective

Correlating Parkinson’s disease motor symptoms with three-dimensional [18F]FP-CIT PET

Persistence of lymphocytopenia with CT abnormalities among patients with critical H7N9 swine-origin influenza A virus infection

Atypical pyogenic brain abscess evaluation by diffusion-weighted imaging: diagnosis with multimodality MR imaging

CT measurement of splenic volume changes as a result of hypovolemic shock

Added value of a single-energy projection-based metal-artifact reduction algorithm for the computed tomography evaluation of oral cavity cancers